rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Andrew R. Allen

Director

Company insider

Files Form 4 as: Director, Cullinan Therapeutics; Director, Adaptimmune Therapeutics; President and CEO, Gritstone bio; Director, Tcr2 Therapeutics; Director and 10% owner, Sierra Oncology; Director, Epizyme; Officer, Clovis Oncology; Chief Medical Officer, EVP, Pharmion.

Every Form 4 they filed

In numbers

Trades disclosed
120
Buys
2
Sells
6
Bought
$158K
Sold
$12.1M
Companies
8
Companies where not an officer
5
First trade
1 Sep 2006
Last trade
16 Jun 2026
Last filed
18 Jun 2026

Companies traded

Where they are an officer
Gritstone bioDirector, Officer · last 24 Jun 20240 buys · 1 sell
Clovis OncologyOfficer · last 2 Mar 20151 buy · 5 sells
PharmionOfficer · last 7 Mar 20080 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
CGEM Cullinan TherapeuticsDirector · Biotechnology · last 16 Jun 20260 buys · 0 sells
Adaptimmune TherapeuticsDirector · last 1 Jul 20240 buys · 0 sells
Tcr2 TherapeuticsDirector · last 1 Jun 20230 buys · 0 sells
Sierra OncologyDirector, 10% owner · last 1 Jul 20221 buy · 0 sells
EpizymeDirector · last 11 Jun 20210 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
16 Jun 2026filed 18 Jun 2026CGEM Cullinan Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—21,781 at $0.00filing
16 Jun 2026filed 18 Jun 2026CGEM Cullinan Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—21,781 at $0.00filing
7 Aug 2025filed 8 Aug 2025CGEM Cullinan Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—79,456 at $0.00filing
1 Jul 2024filed 1 Jul 2024Adaptimmune Therapeuticsoption or derivativeSEC FORM 4 Code A—660,000 at $0.00filing
24 Jun 2024filed 26 Jun 2024Gritstone bioSEC FORM 4 Code G—325,000 at $0.00filing
24 Jun 2024filed 26 Jun 2024Gritstone bioSEC FORM 4 Code G—325,000 at $0.00filing
16 May 2024filed 17 May 2024Gritstone bioSEC FORM 4 Sold$18K24,263 at $0.75filing
15 May 2024filed 17 May 2024Gritstone biooption or derivativeSEC FORM 4 Code A—615,000 at $0.00filing
15 May 2024filed 17 May 2024Gritstone bioSEC FORM 4 Code A—47,873 at $0.00filing
1 Feb 2024filed 5 Feb 2024Gritstone biooption or derivativeSEC FORM 4 Code A—615,000 at $0.00filing
1 Feb 2024filed 5 Feb 2024Gritstone bioSEC FORM 4 Code A—105,000 at $0.00filing
5 Jul 2023filed 5 Jul 2023Adaptimmune Therapeuticsoption or derivativeSEC FORM 4 Code A—73,212 at $0.00filing
5 Jul 2023filed 5 Jul 2023Adaptimmune Therapeuticsoption or derivativeSEC FORM 4 Code A—56,868 at $0.00filing
5 Jul 2023filed 5 Jul 2023Adaptimmune Therapeuticsoption or derivativeSEC FORM 4 Code A—45,348 at $0.00filing
5 Jul 2023filed 5 Jul 2023Adaptimmune Therapeuticsoption or derivativeSEC FORM 4 Code A—109,746 at $0.00filing
5 Jul 2023filed 5 Jul 2023Adaptimmune Therapeuticsoption or derivativeSEC FORM 4 Code A—109,746 at $0.00filing
5 Jul 2023filed 5 Jul 2023Adaptimmune Therapeuticsoption or derivativeSEC FORM 4 Code A—152,376 at $0.00filing
3 Jul 2023filed 3 Jul 2023Adaptimmune Therapeuticsoption or derivativeSEC FORM 4 Code A—500,000 at $0.00filing
1 Jun 2023filed 1 Jun 2023Tcr2 Therapeuticsoption or derivativeSEC FORM 4 Code D—16,800 at $0.00filing
1 Jun 2023filed 1 Jun 2023Tcr2 Therapeuticsoption or derivativeSEC FORM 4 Code D—12,100 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed8

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.